Translating “Translation and Diagnostics” – bridging the third translational gap
Lead Research Organisation:
Newcastle University
Department Name: UNLISTED
Abstract
Abstracts are not currently available in GtR for all funded research. This is normally because the abstract was not required at the time of proposal submission, but may be because it included sensitive information such as personal details.
Technical Summary
The MRC Proximity to Discovery scheme awards universities funds to help develop new collaborations, and ways of exchanging knowledge and skills. The awards can be used to support activities that promote the value of academic-industry partnership, and enhance academic and industry researchers’ understanding of each other’s needs and capabilities. This may be through people exchanges, creation of technology demonstrators, showcase events, commercialisation workshops and ‘entrepreneurs in residence’ schemes. Such exchanges of knowledge and skills will boost the most fruitful collaborations between UK universities and life science companies.
Organisations
- Newcastle University (Lead Research Organisation)
- AbbVie Inc (Collaboration)
- Croda International (Collaboration)
- Wellcome Trust (Collaboration)
- LEO Pharma (including subsidiary Peplin Ltd) (Collaboration)
- Sanofi (Collaboration)
- National Eczema Society (Collaboration)
- GlaxoSmithKline (GSK) (Collaboration)
- Eczema Outreach (Scotland) (Collaboration)
- British Association of Dermatologists (BAD) (Collaboration)
People |
ORCID iD |
Publications
Tsakok T
(2019)
Association of Serum Ustekinumab Levels With Clinical Response in Psoriasis.
in JAMA dermatology
Ritchlin CT
(2020)
Moving Toward Precision Medicine in Psoriasis and Psoriatic Arthritis
in J Rheumatol Suppl.
Abuabara K
(2021)
Priority research questions in atopic dermatitis: an International Eczema Council eDelphi consensus.
in The British journal of dermatology
Grantham HJ
(2019)
The devil is in the data: differences in drug persistence between SNIIRAM, the French national health insurance database, and psoriasis biologics intervention registers.
in The British journal of dermatology
Pan S
(2020)
Using Real-World Data to Guide Ustekinumab Dosing Strategies for Psoriasis: A Prospective Pharmacokinetic-Pharmacodynamic Study.
in Clinical and translational science
Watson N
(2019)
Ustekinumab exposure during conception and pregnancy in patients with chronic plaque psoriasis: a case series of 10 pregnancies.
in The British journal of dermatology
| Description | CRUK Accelerator Award: HUNTER: Hepatocellular Carcinoma Expediter Network |
| Amount | £5,000,000 (GBP) |
| Funding ID | C9380/A28223 & A26813 |
| Organisation | Cancer Research UK |
| Sector | Charity/Non Profit |
| Country | United Kingdom |
| Start | 12/2018 |
| End | 11/2023 |
| Description | Effect of Lonza supplied components (actives/botanicals) on the microbiota of healthy skin- PhD study |
| Amount | £97,507 (GBP) |
| Organisation | Lonza Group |
| Sector | Private |
| Country | Global |
| Start | 10/2018 |
| End | 09/2021 |
| Description | Evaluation of nicotine and its analogues to remediate dyskinesias and cognitive deficits associated with Parkinson's disease |
| Amount | £294,180 (GBP) |
| Funding ID | G-1805 |
| Organisation | Parkinson's UK |
| Sector | Charity/Non Profit |
| Country | United Kingdom |
| Start | 01/2019 |
| End | 01/2021 |
| Description | Functional and genomic characterisation of ultraviolet-B on involved and uninvolved psoriatic skin: application towards understanding of environmental stress effects on ageing and cancer risk. |
| Amount | £118,487 (GBP) |
| Organisation | National Institute for Health Research |
| Department | NIHR Biomedical Research Centre |
| Sector | Public |
| Country | United Kingdom |
| Start | 02/2018 |
| End | 01/2021 |
| Description | Functional and single-cell genomic characterisation of atopic dermatitis endotypes |
| Amount | £231,354 (GBP) |
| Funding ID | BH180448 |
| Organisation | National Institute for Health Research |
| Department | NIHR Biomedical Research Centre |
| Sector | Public |
| Country | United Kingdom |
| Start | 05/2018 |
| End | 04/2021 |
| Description | ICURe ASTEROID, the fun 3D eye test. |
| Amount | £29,980 (GBP) |
| Organisation | Higher Education Funding Council for England |
| Sector | Public |
| Country | United Kingdom |
| Start | 05/2017 |
| End | 08/2017 |
| Description | ICURe Cohort 8 AMLO-a novel prognostic test for melanoma disease progression |
| Amount | £35,000 (GBP) |
| Funding ID | 08-02/514603916 |
| Organisation | Higher Education Funding Council for England |
| Sector | Public |
| Country | United Kingdom |
| Start | 03/2017 |
| End | 06/2017 |
| Description | LITMUS |
| Amount | £3,321,092 (GBP) |
| Funding ID | 777377 |
| Organisation | European Commission |
| Sector | Public |
| Country | European Union (EU) |
| Start | 10/2017 |
| End | 10/2022 |
| Description | MICA-Molecular drivers of fibrosis at the hepatic epithelial-mesenchymal barrier |
| Amount | £1,871,277 (GBP) |
| Funding ID | MR/R023026/1 |
| Organisation | Medical Research Council (MRC) |
| Sector | Public |
| Country | United Kingdom |
| Start | 01/2019 |
| End | 01/2024 |
| Description | NICE AdviSeMe Prize for its novel prognostic skin cancer test AMBLor |
| Amount | £15,000 (GBP) |
| Organisation | National Institute for Health and Care Excellence (NICE) |
| Sector | Public |
| Country | United Kingdom |
| Start | 01/2018 |
| Description | NIHR HTA: Optimal surveillance strategies for grade I melanoma: An evidence synthesis and economic modelling |
| Amount | £262,200 (GBP) |
| Organisation | National Institute for Health Research |
| Sector | Public |
| Country | United Kingdom |
| Start | 05/2018 |
| End | 07/2019 |
| Description | NIHR Senior Investigator Award |
| Amount | £60,000 (GBP) |
| Funding ID | NIHR200168 |
| Organisation | National Institute for Health Research |
| Sector | Public |
| Country | United Kingdom |
| Start | 04/2019 |
| End | 03/2023 |
| Description | Newcastle University EPSRC IAA - Using in silico and cell biology approaches to determine the protective of effects of Hexis Lab provided actives on mitochondrial DNA damage and bioenergy biomarkers in human skin cells subjected to oxidative stress |
| Amount | £23,495 (GBP) |
| Organisation | Engineering and Physical Sciences Research Council (EPSRC) |
| Sector | Public |
| Country | United Kingdom |
| Start | 12/2017 |
| End | 05/2018 |
| Description | Newcastle University Northern Accelerator - European Structural and Investment Funds for ALMo |
| Amount | £25,000 (GBP) |
| Organisation | Government of the UK |
| Sector | Public |
| Country | United Kingdom |
| Start | 09/2017 |
| End | 03/2018 |
| Description | Towards targeting neutrophils in hepatocellular carcinoma |
| Amount | £941,943 (GBP) |
| Funding ID | A23390 |
| Organisation | Cancer Research UK |
| Sector | Charity/Non Profit |
| Country | United Kingdom |
| Start | 03/2017 |
| End | 02/2022 |
| Description | i4i Innovative diagnostic test for early stage, high risk, melanoma AMLo |
| Amount | £1,005,680 (GBP) |
| Funding ID | II-LA-0417-20001 |
| Organisation | National Institute for Health Research |
| Sector | Public |
| Country | United Kingdom |
| Start | 06/2018 |
| End | 11/2020 |
| Description | iCURE - ALMo |
| Amount | £218,000 (GBP) |
| Organisation | Innovate UK |
| Sector | Public |
| Country | United Kingdom |
| Start | 10/2017 |
| End | 03/2018 |
| Description | MRC Proximity to Discovery: UK TREND Atopic Eczema Stratified Medicine Workshop |
| Organisation | AbbVie Inc |
| Department | Translational Immunology Department |
| Country | Global |
| Sector | Private |
| PI Contribution | Initiated, organised and chaired by Professor Reynolds, the PtD: UK TREND atopic eczema stratified medicine workshop, built on the successful PtD: Rheumatology/Dermatology Theme week held in February 2016 and the development of an atopic eczema stratified medicine theme by UK TREND. This workshop presented an excellent opportunity to engage with key individuals and centres focused in atopic eczema research. |
| Collaborator Contribution | The event was initiated, organised and chaired by Professor Reynolds who also presented at the event. Two further presentations were made by academics from Newcastle University. The contribution from Industry included staff time and expenses to attend the event, including 3 US flights (Abbvie), 1 European (LEO Pharma), and UK based staff travelling to the event. Abbvie estimated that this amounted to an in-kind contribution of £17,800. The British Association of Dermatologists provided staff support in the organisation of the event, and covered the expenses of some of the delegates. They will continue to work with us on future collaborations in this area. |
| Impact | No formal outputs and outcomes at this stage, although it is planned that formal collaborations will continue as a result of the initiative, leading to a UK-wide consortium focused on stratified medicine in Atopic Eczema. |
| Start Year | 2016 |
| Description | MRC Proximity to Discovery: UK TREND Atopic Eczema Stratified Medicine Workshop |
| Organisation | British Association of Dermatologists (BAD) |
| Country | United Kingdom |
| Sector | Charity/Non Profit |
| PI Contribution | Initiated, organised and chaired by Professor Reynolds, the PtD: UK TREND atopic eczema stratified medicine workshop, built on the successful PtD: Rheumatology/Dermatology Theme week held in February 2016 and the development of an atopic eczema stratified medicine theme by UK TREND. This workshop presented an excellent opportunity to engage with key individuals and centres focused in atopic eczema research. |
| Collaborator Contribution | The event was initiated, organised and chaired by Professor Reynolds who also presented at the event. Two further presentations were made by academics from Newcastle University. The contribution from Industry included staff time and expenses to attend the event, including 3 US flights (Abbvie), 1 European (LEO Pharma), and UK based staff travelling to the event. Abbvie estimated that this amounted to an in-kind contribution of £17,800. The British Association of Dermatologists provided staff support in the organisation of the event, and covered the expenses of some of the delegates. They will continue to work with us on future collaborations in this area. |
| Impact | No formal outputs and outcomes at this stage, although it is planned that formal collaborations will continue as a result of the initiative, leading to a UK-wide consortium focused on stratified medicine in Atopic Eczema. |
| Start Year | 2016 |
| Description | MRC Proximity to Discovery: UK TREND Atopic Eczema Stratified Medicine Workshop |
| Organisation | Croda International |
| Country | United Kingdom |
| Sector | Private |
| PI Contribution | Initiated, organised and chaired by Professor Reynolds, the PtD: UK TREND atopic eczema stratified medicine workshop, built on the successful PtD: Rheumatology/Dermatology Theme week held in February 2016 and the development of an atopic eczema stratified medicine theme by UK TREND. This workshop presented an excellent opportunity to engage with key individuals and centres focused in atopic eczema research. |
| Collaborator Contribution | The event was initiated, organised and chaired by Professor Reynolds who also presented at the event. Two further presentations were made by academics from Newcastle University. The contribution from Industry included staff time and expenses to attend the event, including 3 US flights (Abbvie), 1 European (LEO Pharma), and UK based staff travelling to the event. Abbvie estimated that this amounted to an in-kind contribution of £17,800. The British Association of Dermatologists provided staff support in the organisation of the event, and covered the expenses of some of the delegates. They will continue to work with us on future collaborations in this area. |
| Impact | No formal outputs and outcomes at this stage, although it is planned that formal collaborations will continue as a result of the initiative, leading to a UK-wide consortium focused on stratified medicine in Atopic Eczema. |
| Start Year | 2016 |
| Description | MRC Proximity to Discovery: UK TREND Atopic Eczema Stratified Medicine Workshop |
| Organisation | Eczema Outreach (Scotland) |
| Country | United Kingdom |
| Sector | Charity/Non Profit |
| PI Contribution | Initiated, organised and chaired by Professor Reynolds, the PtD: UK TREND atopic eczema stratified medicine workshop, built on the successful PtD: Rheumatology/Dermatology Theme week held in February 2016 and the development of an atopic eczema stratified medicine theme by UK TREND. This workshop presented an excellent opportunity to engage with key individuals and centres focused in atopic eczema research. |
| Collaborator Contribution | The event was initiated, organised and chaired by Professor Reynolds who also presented at the event. Two further presentations were made by academics from Newcastle University. The contribution from Industry included staff time and expenses to attend the event, including 3 US flights (Abbvie), 1 European (LEO Pharma), and UK based staff travelling to the event. Abbvie estimated that this amounted to an in-kind contribution of £17,800. The British Association of Dermatologists provided staff support in the organisation of the event, and covered the expenses of some of the delegates. They will continue to work with us on future collaborations in this area. |
| Impact | No formal outputs and outcomes at this stage, although it is planned that formal collaborations will continue as a result of the initiative, leading to a UK-wide consortium focused on stratified medicine in Atopic Eczema. |
| Start Year | 2016 |
| Description | MRC Proximity to Discovery: UK TREND Atopic Eczema Stratified Medicine Workshop |
| Organisation | GlaxoSmithKline (GSK) |
| Country | Global |
| Sector | Private |
| PI Contribution | Initiated, organised and chaired by Professor Reynolds, the PtD: UK TREND atopic eczema stratified medicine workshop, built on the successful PtD: Rheumatology/Dermatology Theme week held in February 2016 and the development of an atopic eczema stratified medicine theme by UK TREND. This workshop presented an excellent opportunity to engage with key individuals and centres focused in atopic eczema research. |
| Collaborator Contribution | The event was initiated, organised and chaired by Professor Reynolds who also presented at the event. Two further presentations were made by academics from Newcastle University. The contribution from Industry included staff time and expenses to attend the event, including 3 US flights (Abbvie), 1 European (LEO Pharma), and UK based staff travelling to the event. Abbvie estimated that this amounted to an in-kind contribution of £17,800. The British Association of Dermatologists provided staff support in the organisation of the event, and covered the expenses of some of the delegates. They will continue to work with us on future collaborations in this area. |
| Impact | No formal outputs and outcomes at this stage, although it is planned that formal collaborations will continue as a result of the initiative, leading to a UK-wide consortium focused on stratified medicine in Atopic Eczema. |
| Start Year | 2016 |
| Description | MRC Proximity to Discovery: UK TREND Atopic Eczema Stratified Medicine Workshop |
| Organisation | LEO Pharma (including subsidiary Peplin Ltd) |
| Country | Denmark |
| Sector | Private |
| PI Contribution | Initiated, organised and chaired by Professor Reynolds, the PtD: UK TREND atopic eczema stratified medicine workshop, built on the successful PtD: Rheumatology/Dermatology Theme week held in February 2016 and the development of an atopic eczema stratified medicine theme by UK TREND. This workshop presented an excellent opportunity to engage with key individuals and centres focused in atopic eczema research. |
| Collaborator Contribution | The event was initiated, organised and chaired by Professor Reynolds who also presented at the event. Two further presentations were made by academics from Newcastle University. The contribution from Industry included staff time and expenses to attend the event, including 3 US flights (Abbvie), 1 European (LEO Pharma), and UK based staff travelling to the event. Abbvie estimated that this amounted to an in-kind contribution of £17,800. The British Association of Dermatologists provided staff support in the organisation of the event, and covered the expenses of some of the delegates. They will continue to work with us on future collaborations in this area. |
| Impact | No formal outputs and outcomes at this stage, although it is planned that formal collaborations will continue as a result of the initiative, leading to a UK-wide consortium focused on stratified medicine in Atopic Eczema. |
| Start Year | 2016 |
| Description | MRC Proximity to Discovery: UK TREND Atopic Eczema Stratified Medicine Workshop |
| Organisation | National Eczema Society |
| Country | United Kingdom |
| Sector | Learned Society |
| PI Contribution | Initiated, organised and chaired by Professor Reynolds, the PtD: UK TREND atopic eczema stratified medicine workshop, built on the successful PtD: Rheumatology/Dermatology Theme week held in February 2016 and the development of an atopic eczema stratified medicine theme by UK TREND. This workshop presented an excellent opportunity to engage with key individuals and centres focused in atopic eczema research. |
| Collaborator Contribution | The event was initiated, organised and chaired by Professor Reynolds who also presented at the event. Two further presentations were made by academics from Newcastle University. The contribution from Industry included staff time and expenses to attend the event, including 3 US flights (Abbvie), 1 European (LEO Pharma), and UK based staff travelling to the event. Abbvie estimated that this amounted to an in-kind contribution of £17,800. The British Association of Dermatologists provided staff support in the organisation of the event, and covered the expenses of some of the delegates. They will continue to work with us on future collaborations in this area. |
| Impact | No formal outputs and outcomes at this stage, although it is planned that formal collaborations will continue as a result of the initiative, leading to a UK-wide consortium focused on stratified medicine in Atopic Eczema. |
| Start Year | 2016 |
| Description | MRC Proximity to Discovery: UK TREND Atopic Eczema Stratified Medicine Workshop |
| Organisation | Sanofi |
| Country | Global |
| Sector | Private |
| PI Contribution | Initiated, organised and chaired by Professor Reynolds, the PtD: UK TREND atopic eczema stratified medicine workshop, built on the successful PtD: Rheumatology/Dermatology Theme week held in February 2016 and the development of an atopic eczema stratified medicine theme by UK TREND. This workshop presented an excellent opportunity to engage with key individuals and centres focused in atopic eczema research. |
| Collaborator Contribution | The event was initiated, organised and chaired by Professor Reynolds who also presented at the event. Two further presentations were made by academics from Newcastle University. The contribution from Industry included staff time and expenses to attend the event, including 3 US flights (Abbvie), 1 European (LEO Pharma), and UK based staff travelling to the event. Abbvie estimated that this amounted to an in-kind contribution of £17,800. The British Association of Dermatologists provided staff support in the organisation of the event, and covered the expenses of some of the delegates. They will continue to work with us on future collaborations in this area. |
| Impact | No formal outputs and outcomes at this stage, although it is planned that formal collaborations will continue as a result of the initiative, leading to a UK-wide consortium focused on stratified medicine in Atopic Eczema. |
| Start Year | 2016 |
| Description | MRC Proximity to Discovery: UK TREND Atopic Eczema Stratified Medicine Workshop |
| Organisation | Wellcome Trust |
| Department | Wellcome Trust Bloomsbury Centre |
| Country | United Kingdom |
| Sector | Charity/Non Profit |
| PI Contribution | Initiated, organised and chaired by Professor Reynolds, the PtD: UK TREND atopic eczema stratified medicine workshop, built on the successful PtD: Rheumatology/Dermatology Theme week held in February 2016 and the development of an atopic eczema stratified medicine theme by UK TREND. This workshop presented an excellent opportunity to engage with key individuals and centres focused in atopic eczema research. |
| Collaborator Contribution | The event was initiated, organised and chaired by Professor Reynolds who also presented at the event. Two further presentations were made by academics from Newcastle University. The contribution from Industry included staff time and expenses to attend the event, including 3 US flights (Abbvie), 1 European (LEO Pharma), and UK based staff travelling to the event. Abbvie estimated that this amounted to an in-kind contribution of £17,800. The British Association of Dermatologists provided staff support in the organisation of the event, and covered the expenses of some of the delegates. They will continue to work with us on future collaborations in this area. |
| Impact | No formal outputs and outcomes at this stage, although it is planned that formal collaborations will continue as a result of the initiative, leading to a UK-wide consortium focused on stratified medicine in Atopic Eczema. |
| Start Year | 2016 |
| Company Name | AMLo Biosciences Limited |
| Description | AMLo Biosciences has identified two proteins (AMBLor) in the epidermis overlying the primary tumour that are lost in high-risk melanoma that can be assessed using standard automated immunohistochemistry, fitting seamlessly into existing pathology procedures. AMBLor has been validated in over 400 melanoma Stage I biopsies classified under the new 8th edition of AJCC staging, with known clinical outcomes. Use of this test can accurately predict melanomas that are genuinely low-risk and those that are high-risk with greater sensitivity and specificity than any other prognostic melanoma test. AMBLor also gives better prognostic information than SLNB in tumours with Breslow depth <2mm. AMLo Biosciences intends to produce a diagnostic kit to assess AMBLor in tumour tissue biopsies suitable for use in pathology labs worldwide with real potential to reduce costs to healthcare services, provide reassurance and improve patient outcomes. |
| Year Established | 2017 |
| Impact | it is still too early in the company for this, they are still fundrasing. |
| Website | https://amlo-biosciences.com/ |
| Description | Adopting MedTech for Patient Benefit 2017 |
| Form Of Engagement Activity | Participation in an activity, workshop or similar |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Professional Practitioners |
| Results and Impact | The event was delivered by the NIHR DEC Newcastle in conjunction with Newcastle Hospitals' Regional Medical Physics Department, and with the support of the Academic Health Science Network (AHSN) for North East & North Cumbria. The event was attended by 90 delegates from across the country, and focused on helping companies to better understand the evidence required for the adoption of in vitro diagnostics (IVDs) and other medical technologies for patient benefit within the NHS. |
| Year(s) Of Engagement Activity | 2016 |
| URL | http://www.newcastle.dec.nihr.ac.uk/adopting-medtech-2017 |
| Description | 'Molecular Diagnostics at Newcastle' |
| Form Of Engagement Activity | Participation in an activity, workshop or similar |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Professional Practitioners |
| Results and Impact | The Node recently took part in the Newcastle University NAHP Industry Month with a day-long event to showcase Node-related work. The title for the event was 'Molecular Diagnostics at Newcastle' and it was held on the 2nd March 2017. The purpose of the event was to bring industry together with the Node research community to identify potential collaboration opportunities around molecular diagnostics and image analysis. |
| Year(s) Of Engagement Activity | 2017 |
| URL | http://www.newcastlepathnode.org.uk/2017/03/molecular-diagnostics-newcastle-node-industry-event/ |
| Description | Chair plenary session Virtual Conference European Dermatology Forum |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Professional Practitioners |
| Results and Impact | Face to face meeting was cancelled due to COVID. A virtual meeting was held at which 4 plenary talks were presented from international high-level speakers. I co-chaired and introduced 2 speakers. |
| Year(s) Of Engagement Activity | 2022 |
| Description | Diagnostic North East, Virtual Conference: closing remarks |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Geographic Reach | Regional |
| Primary Audience | Professional Practitioners |
| Results and Impact | Promotion and description of Diagnostics North East to increase engagement and activity. |
| Year(s) Of Engagement Activity | 2021 |
| URL | https://diagnosticsnortheast.org.uk/ |
| Description | EIT Health: Innovation Day |
| Form Of Engagement Activity | Participation in an activity, workshop or similar |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Postgraduate students |
| Results and Impact | EIT Health Innovation Day was aimed at boosting the entrepreneurial spirit among students from different disciplines and kick-starting innovation in the area of health and ageing. Inspirational speakers shared their experiences of the possibilities and rewards of health innovation and each delegate had the opportunity to develop a real viable health innovation product or idea to solve local health challenges. EIT Health Innovation Day was a European wide event that will occured on Friday 18th November in Sweden and Denmark and Saturday 19th November in the UK. |
| Year(s) Of Engagement Activity | 2016 |
| URL | https://www.eventbrite.com/e/eit-health-innovation-day-imperial-oxford-and-newcastle-tickets-2524062... |
| Description | ESDR International Eczema Council: chair Human Models of Atopic Dermatitis symposium and introductory remarks; |
| Form Of Engagement Activity | A formal working group, expert panel or dialogue |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Professional Practitioners |
| Results and Impact | Introduction about the area and the IEC, brief presentations from each of the panel and then a round table discussion. |
| Year(s) Of Engagement Activity | 2021 |
| URL | https://www.eczemacouncil.org/index.php?option=com_jevents&task=icalrepeat.detail&evid=48&Itemid=115... |
| Description | MRC Proximity to Discovery: UK TREND Atopic Eczema Stratified Medicine Workshop (2016 - Still Active) |
| Form Of Engagement Activity | Participation in an activity, workshop or similar |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Professional Practitioners |
| Results and Impact | Hosted by Professor Reynolds, he PtD: UK TREND atopic eczema stratified medicine workshop, built on the successful PtD: Rheumatology/Dermatology Theme week held in February 2016 and the development of an atopic eczema stratified medicine theme by UK TREND. This workshop presented an excellent opportunity to engage with key individuals and centres focused in atopic eczema research. The significant unmet clinical need, discovery of FLG mutations predisposing to atopic eczema and particular sub-phenotypes, recent insight into other genetic and environmental risk factors and emerging biological therapies, means that atopic eczema provides an important paradigm for a stratified medicine approach. Moreover, the NIHR infrastructure and our established collaborations means that the UK is uniquely placed to deliver such an integrative and multidisciplinary project. We invited interested physicians, researchers, potential industrial partners, stake holders and patient representatives to be involved from the start. Our plans are to work together over a 12-month period to construct a credible case for support that would enable the formulation of grant applications. |
| Year(s) Of Engagement Activity | 2017 |
| URL | http://www.newcastleptd.com/uktrend/ |
| Description | Presentation - EAACI Digital Conference |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Professional Practitioners |
| Results and Impact | Presentation title: Human and computational models of immune mediated inflammatory skin disease: challenges, insights and perspectives |
| Year(s) Of Engagement Activity | 2020 |
| Description | Rudi Cormane Lecture, ESDR, Bordeaux, France |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Professional Practitioners |
| Results and Impact | I presented the Rudi Cormane lecture entitled "A systems biology and computational modelling approach to inflammatory skin disease" at the ESDR meeting in Bordeaux. |
| Year(s) Of Engagement Activity | 2019 |
| URL | https://esdrmeeting.org/index.php/sessions/rudi-cormane-lecture/ |
| Description | Taking biomarker discovery through to implementation - presentation at BIONOW Meeting |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Geographic Reach | Regional |
| Primary Audience | Industry/Business |
| Results and Impact | Bionow is a not for profit membership organisation supporting the biomedical, pharma and life sciences sectors across the North of England. Bionow does this by bringing people together at our exciting conferences and events across the North, being an advocate for the North, and providing comprehensive procurement member benefits that strengthen the competitiveness of the North's innovative life science sector. This presentation formed part of one of their regular events aimed at increasing awareness of the sector. |
| Year(s) Of Engagement Activity | 2018 |
| URL | https://www.bionow.co.uk/ |
| Description | UK TREND / Stratified Medicine follow-on Meeting, London |
| Form Of Engagement Activity | A formal working group, expert panel or dialogue |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Professional Practitioners |
| Results and Impact | UK TREND Atopic Eczema Stratified Medicine follow-on meeting (hosted at the British Association of Dermatologists (BAD) in London). This second workshop, convened to strengthen the work of the first workshop in specific areas, has resulted in more carefully defined work streams, and led to a greater understanding of the potential contributions from collaborators (including Pharma). Collaborations with industry were strengthened (both new and existing relationships); 7 fully engaged industrial partners attended, along with 3 patient representatives, and 18 potential collaborators from other UK Universities and the NHS. Five companies were represented - Sanofi, GSK and Croda (UK), LEO Pharma (1 delegate from Denmark) and Abbvie (3 delegates from US). Expertise was shared and feedback was extremely positive (93% of the feedback graded the meeting as 'very useful' 5/5 overall). The aim of the initiative is to develop a consortium with which to gain funding to further develop projects, and this is ongoing. |
| Year(s) Of Engagement Activity | 2017 |